Metraipolis › archive › dc_29bf6e0282ee

Combination of the First-in-Class Imipridone ONC201 and Standard Anticancer Therapies as a Rational Approach for Therapeutic Benefit — Europe PMC PMID:41020897

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41020897
DOI
10.3390/cimb47090775
License (as archived)
solo-consultazione
Archived
2026-11-09T21:22:08.507Z
SHA-256 of the archived text
c6c130316335bac7cdf45990a0d9b2e3b9ae863206ee17e32c8f1a217939afae
Stable URL of this page
https://metraipolis.com/documento/dc_29bf6e0282ee

How to cite

Combination of the First-in-Class Imipridone ONC201 and Standard Anticancer Therapies as a Rational Approach for Therapeutic Benefit — Europe PMC PMID:41020897 — Europe PMC (en), https://europepmc.org/article/MED/41020897 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_29bf6e0282ee (Metraipolis archive dc_29bf6e0282ee, sha256 c6c130316335bac7cdf45990a0d9b2e3b9ae863206ee17e32c8f1a217939afae)
BibTeX
@misc{dc29bf6e0282ee,
  title = {Combination of the First-in-Class Imipridone ONC201 and Standard Anticancer Therapies as a Rational Approach for Therapeutic Benefit — Europe PMC PMID:41020897},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41020897},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_29bf6e0282ee; sha256 c6c130316335bac7cdf45990a0d9b2e3b9ae863206ee17e32c8f1a217939afae},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41020897. Agents can read the archived copy with the MCP tool read_document.